Everolimus-Eluting Versus Sirolimus-Eluting Stents | Zendy

Antoinette de Waha | Zendy; Alban Dibra | Zendy; Robert A. Byrne | Zendy; Gjin Ndrepepa | Zendy; Julinda Mehilli | Zendy; Massimiliano Fusaro | Zendy; KarlLudwig Laugwitz | Zendy; Steffen Maßberg | Zendy; Albert Schömig | Zendy; Adnan Kastrati | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Everolimus-Eluting Versus Sirolimus-Eluting Stents

Author(s) -

Antoinette de Waha,

Alban Dibra,

Robert A. Byrne,

Gjin Ndrepepa,

Julinda Mehilli,

Massimiliano Fusaro,

KarlLudwig Laugwitz,

Steffen Maßberg,

Albert Schömig,

Adnan Kastrati

Publication year - 2011

Publication title -

circulation cardiovascular interventions

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.621

H-Index - 95

eISSN - 1941-7632

pISSN - 1941-7640

DOI - 10.1161/circinterventions.111.963256

Subject(s) - medicine , hazard ratio , cardiology , myocardial infarction , stent , sirolimus , clinical endpoint , everolimus , coronary artery disease , drug eluting stent , revascularization , confidence interval , surgery , percutaneous coronary intervention , randomized controlled trial

The aim of the study was to compare the outcomes after placement of the everolimus-eluting stent (EES; Xience V) and the sirolimus-eluting stent (SES; Cypher) in patients with coronary artery disease. The second-generation EES is currently one of the most commonly used drug-eluting stents in clinical practice. Although it has clearly been shown superior to paclitaxel-eluting stents, its relative merits against SES have been less extensively assessed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research